Altimmune, Inc. (ALT)

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune Q2 Earnings Call Highlights

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune's Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune's drug meets main goal of mid-stage study for alcohol use disorder

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

5 Small Drug Stocks to Invest in Amid a Biotech Comeback

Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript